By UGA Biopharma…
To get in touch with UGA Biopharma GmbH, simply fill out the form below.
Subscribe to Supplier
UGA Biopharma to showcase their Cell line development platform at BIO-Europe® Digital
Hennigsdorf near Berlin, Germany: UGA Biopharma GmbH, the leading-edge contract development and research organization for biologics and biosimilars, will once again be a high-profile presence at the upcoming BIO-Europe® biotech industry partnering event, to be hosted in digital online format for Autumn 2021.
UGA Biopharma, which has a long relationship with the BIO-Europe conference, will use October’s BIO-Europe® Digital Edition to connect with potential customers for its fast-track cell line development platforms, ready-to-use biosimilar cell lines, and its First CHOice® Media and Feeds.
First CHOice benefits
UGA will present the user benefits of the First CHOice® Medium for high performance cell culture optimized for mammalian cell lines. In combination with CHOice® Feeds it has been optimized to boost the cell growth and productivity in batch, fed-batch and perfusion processes.
The completely chemically defined, animal component and protein free First CHOice® Medium has been developed in close cooperation with customers using CHO-S, CHO-DG44 and CHO-K1 cell lines in order to minimize stress-related metabolites such as lactate and ammonia, to guarantee high product quality and cell viability during all cultivation phases.
The team will be able to demonstrate product capabilities using the event’s partneringONE® virtual meeting platform, as well as UGA Biopharma’s overall strengths as a contract research and development organization (CRDO) focusing on the development of stable expressing CHO cell lines for the production of biologics and biosimilars for biopharmaceutical companies.
Upstream and downstream process support
Business Development & Marketing Manager, Dr. Marcel Nowak, will be representing UGA Biopharma online. He commented: “We will be reaching out in particular to biopharma manufacturers, research institutions (universities, research institutes, etc.) as well as start-ups and other CROs that need to outsource cell line development (CLD), upstream or downstream processing. We will be very clear about UGA’s core mission to fulfill customer requests, recognizing industry needs for high titer, high quality and fast delivery timelines. UGA generates robust CHO-DG44 cell lines, reaching titers from 4 to 7 g/L, within four months of receiving the originator sequence,” Dr. Nowak added.
About UGA Biopharma
UGA Biopharma GmbH is an experienced contract research and development organization of biologics and biosimilars with the capabilities to handle all necessary steps from cell line development and bioprocess development to the development of purification strategies and appropriate analytics.
The company supplies its customers in Germany and abroad from its headquarter in Hennigsdorf, near Berlin. Several clients have used UGA products in clinical trials or in products that have received market authorization.
UGA Biopharma GmbH CRDO activities are centered on cell line development for biologics and biosimilars, specializing in the development of stable expressing CHO cell lines and cell media for the production of biologics and biosimilars for biopharmaceutical companies. Typical clients are biopharma manufacturers, research institutions (like universities and research institutes) as well as start-ups and other CROs that need to outsource CLD, upstream, and/or downstream processing.
UGA’s mission is to fulfil customer requests, recognizing industry needs for high titer, high quality and fast delivery timelines, along with robust CHO cell lines. To this end, UGA can deliver cell lines, reaching titers from 4 to 7 g/L, within four months of receiving the originator sequence.
UGA has also developed its proprietary First CHOice® cell culture media and feeds platform to boost the productivity of cell lines. Furthermore, UGA Biopharma GmbH offers ready-to-use biosimilar cell lines, which allow clients interested in biosimilar development fast track access to a highly biosimilar cell line.
Further information at: www.ugabiopharma.com.
About BIO-Europe® Digital 2021
BIO-Europe® is a premier partnering conference that annually attracts an international “who’s who” from biotech, pharma and finance for high caliber networking.
For Autumn 2021, the conference will be hosted digitally online, with both ‘live’ and on-demand elements. It will once again be a four day event, opening October 25. BIO-Europe Digital will feature three on demand content streams, focusing on Business Development, Therapeutic applications and the Biotech Ecosystem.
Featuring a sophisticated partnering system, partneringONE®, the digital event will enable networking and meetings between financiers, innovators and companies across the life science value chain, from large biotech to start-ups.
The event is organized by Informa Connect and EBD Group with more information at: https://informaconnect.com/bioeurope/
Click on UGA Biopharma First CHOice Medium and Feeds for more information.